Market Insight - Avoiding bribery risk 2: world focus
This article was originally published in Scrip
In the second of two Market Insight articles highlighting to pharma the dangers of bribery risk, Jeremy Cole and Marc Dalby explain why regulators are taking an increasingly hard line on multinationals and their more dubious business relationships
You may also be interested in...
Pierre Bourdage, global head of biopharmaceuticals at Sandoz, has hit back at false statements and misleading claims around biosimilars that persist despite mounting evidence to the contrary.
A recent Spanish self-care and cosmetics industry conference organized by ANEFP and Beauty Cluster explores the commercial opportunity in China via online marketplace Tmall.
Australia’s NeuClone expects to be among the first biosimilar market entrants to challenge Stelara, with the firm’s NeuLara ustekinumab rival reporting positive Phase I data as the company prepares to move ahead with Phase III trials next year.